Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension

作者：Shraddha Narechania, Heather Torbic, Adriano R. Tonelli · 发表于：Journal of Cardiovascular Pharmacology and Therapeutics · 年份：2019 · DOI：10.1177/1074248419877409 · 被引用次数：34 · 研究领域：Pulmonary Hypertension Research and Treatments、Heart Failure Treatment and Management、Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Pulmonary arterial hypertension (PAH) is a progressive disease, which can be potentially fatal. The management of a complex disease like PAH requires a multidisciplinary approach from a team consisting of physicians, nurses, social workers, and pharmacists. Adherence to PAH-specific therapy is one of the key factors in the management of this disease. Poor adherence to treatment is a common problem in PAH as it is in many chronic diseases. Management of medication interruptions is a challenge in patients with PAH that can lead to negative consequences. However, for most PAH-specific drugs, there are no clear guidelines on how to manage temporary or abrupt medication discontinuations. In this review, we summarized the available literature and provide suggestions on how to manage interruptions of PAH-specific therapies.